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myogenin (2/2) mice display severe skeletal muscle defects despite expressing normal levels of MyoD. The failure of MyoD
to compensate for myogenin could be explained by distinctions in protein function or by differences in patterns of gene
expression. To distinguish between these two possibilities, we compared the abilities of constitutively expressed myogenin
and MyoD to support muscle differentiation in embryoid bodies made from myogenin (2/2) ES cells. Differentiated
mbryoid bodies from wild-type embryonic stem (ES) cells made extensive skeletal muscle, but embryoid bodies from
yogenin (2/2) ES cells had greatly attenuated muscle-forming capacity. The inability of myogenin (2/2) ES cells to
enerate muscle was independent of endogenous MyoD expression. Skeletal muscle was restored in myogenin (2/2) ES cells
y constitutive expression of myogenin. In contrast, constitutive expression of MyoD resulted in only marginal
nhancement of skeletal muscle, although myocyte numbers greatly increased. The results indicated that constitutive
xpression of MyoD led to enhanced myogenic commitment of myogenin (2/2) cells but also indicated that committed
cells were impaired in their ability to form muscle sheets without myogenin. Thus, despite their relatedness, myogenin’s
role in muscle formation is distinct from that of MyoD, and the distinction cannot be explained merely by differences in
their expression properties. © 2000 Academic Press
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Myogenin is a myogenic bHLH transcription factor that
plays essential roles in skeletal muscle differentiation dur-
ing embryogenesis (for recent reviews, see Arnold and
Braun, 2000; Sabourin and Rudnicki, 2000). Knockout mice
lacking the myogenin gene die at birth due to severe
skeletal muscle deficiency (Hasty et al., 1993; Nabeshima
et al., 1993). In these mice, committed myoblasts migrate
to their proper locations but most do not fuse to form
myofibers, indicating that myogenin is required for myo-
blast fusion and differentiation but not for commitment to
the myogenic lineage. Notably, MyoD and myf5 are ex-
1 To whom correspondence should be addressed at The University
of Texas M. D. Anderson Cancer Center, Department of Biochemistry
and Molecular Biology, Box 117, 1515 Holcombe Blvd., Houston, TX
77030. Fax: (713) 790-0329. E-mail: wklein@mdanderson.org.
340pressed at normal levels in myogenin-knockout mice, im-
plying that myogenin’s function in skeletal muscle differ-
entiation cannot be replaced by these closely related bHLH
transcription factors. Despite the importance of the myo-
genic regulatory factors, surprisingly little is known about
why myogenin activates genes in vivo that cannot be
activated by MyoD and myf5.
In contrast to myogenin, MyoD and myf5 function in
myogenic commitment, implying that myogenin lies
downstream of MyoD and myf5 in a genetic regulatory
pathway (reviewed in Yun and Wold, 1996; Arnold and
Braun, 2000; Sabourin and Rudnicki, 2000). However, this
simple view has been recently challenged and found to be
inadequate. As well as having a role in myoblast commit-
ment, MyoD also has a role in myoblast differentiation and
that role is redundant with that of MRF4, the fourth
member of the myogenic regulatory protein family (Rawls
et al., 1998). The redundant functions of MRF4 and MyoD
0012-1606/00 $35.00
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341Myogenin-Deficient ES Cellsappear not to overlap with those of myogenin (Valdez et al.,
2000). Thus, knockout mice reveal roles for MyoD at two
distinct steps in myogenesis, commitment and differentia-
tion, while myf5 appears to play a role solely in commit-
ment, and myogenin and MRF4 play roles solely in differ-
entiation.
The mechanistic basis for the selective function of myo-
genin and the other myogenic regulators remains elusive.
The high degree of sequence divergence among the four
factors outside of the bHLH region implies that each factor
has evolved a specialized role in mammalian myogenesis.
Nevertheless, the spatial, temporal, and quantitative pat-
terns of expression of these factors are not identical, sug-
gesting that the transcription regulatory regions controlling
gene expression are also important in the requirements of
each factor.
One group of investigators has attempted to directly
distinguish between function and regulation of the myo-
genic regulatory factors in vivo. Wang and co-workers
(1996) investigated whether myogenin could functionally
replace myf5 by inserting myogenin into the myf5 locus.
This allele fully rescued the rib defect observed in myf5
(2/2) mice, suggesting that myogenin can replace myf5’s
role in this process (Wang et al., 1996). However, recent
evidence indicates that loss of myf5 is not the true cause of
the rib defect, which makes the suggested functional rela-
tionship between myogenin and myf5 less clear (Kaul et al.,
2000). Moreover, although myogenin inserted into the myf5
locus in a MyoD (2/2) background replaced myf5’s func-
tion in myoblast commitment, it did not rescue skeletal
muscle differentiation when this allele was placed into a
myogenin-null background (Wang and Jaenisch, 1997). Be-
cause myf5 expression precedes that of myogenin by 48 h in
mouse embryos (Sassoon et al., 1989; Ott et al., 1991), and
ecause skeletal muscle formation is highly sensitive to
yogenin levels (Vivian et al., 1999), it is likely that
nsufficient amounts of myogenin were available at the
equired time to restore the muscle defect. These experi-
ents indicate that changes in myogenin’s temporal ex-
ression pattern can dramatically affect its ability to func-
ion as a muscle regulatory protein. However, the
xperiments did not reveal whether other myogenic regu-
atory bHLH proteins could replace myogenin if expressed
nder the same transcriptional control as myogenin.
Functional differences in non-bHLH regions between
yoD and myogenin have been reported by Gerber et al.
1997) using cultured 10T1/2 fibroblasts. Two regions in
yoD appear to be involved in remodeling repressed chro-
atin to mediate transcriptional activation of genes. These
egions are not conserved in myogenin, and functional
ssays show that while MyoD can remodel chromatin,
yogenin cannot. These results are consistent with the role
f MyoD in early specification events and provide a possible
olecular feature in MyoD that distinguishes it from
yogenin.
We were interested in establishing the basis for myoge-in’s specific function in the differentiation of skeletal
Copyright © 2000 by Academic Press. All rightuscle. In particular, we wondered why MyoD cannot
ompensate for myogenin in myogenin (2/2) mice. Perhaps
yoD is capable of functionally replacing myogenin but
he temporal and spatial expression patterns of MyoD are
ufficiently different from those of myogenin so that criti-
al levels of MyoD are not produced at the required time
nd place to mediate the response.
To prove that myogenin’s essential role in myogenesis is
ue to functional specialization and not merely the regula-
ion of its expression, a system is required in which myo-
enin can be removed and other myogenic bHLH factors
dded in its place. Several recent studies have made use of
mbryonic stem (ES) cells to investigate the function of the
yogenic factors (Shani et al., 1992; Braun and Arnold,
994; Weitzer et al., 1995; Dinsmore et al., 1996). Upon
emoval of the growth factor LIF, ES cells can differentiate
nto skeletal, smooth, and cardiac muscle, with each type
xhibiting a characteristic contracting pattern. When ES
ells differentiate into skeletal muscle, the myogenic bHLH
actors are expressed in the same temporal sequence as seen
n vivo (Rohwedel et al., 1994), implying that the myogenic
rogram is faithfully recapitulated in the ES cell system.
oth wild-type ES cells and ES cells lacking myf5 and other
uscle genes have been used to investigate skeletal myo-
enesis. In our laboratory, ES cells have been generated
rom myogenin (2/2) mice (Myer et al., 1997) and exog-
nous genes can be introduced into them by conventional
NA electroporation methods. An advantage of ES cells is
hat multiple ES cell lines derived from a genetically
dentical parental line can be quickly tested for their
uscle-forming properties without the complications asso-
iated with generating knock-in and transgenic mice.
In this report, we describe the features of an ES cell
ifferentiation system in which myogenin (2/2) ES cells do
ot form muscle sheets lacking centralized nuclei while
ild-type ES cells do. Introducing myogenin back into
yogenin (2/2) ES cells by forced expression restored
uscle sheet formation. In contrast, forced expression of
yoD did not lead to muscle sheets. Our results indicate
hat myogenin is functionally distinct from MyoD and that
yoD does not compensate for myogenin in myogenin-
nockout mice because of functional rather than regulatory
ifferences.
MATERIALS AND METHODS
Growth and Differentiation of ES Cells
Wild-type ES cell lines AB1 and AB2.1 were provided by Allan
Bradley, Baylor College of Medicine, and have been described
previously (McMahon and Bradley, 1990; Soriano et al., 1991).
myogenin (1/2) (No. 17) and myogenin (2/2) (No. 18 and 2C1) ES
cell lines were described by Myer et al. (1997). Proliferating ES cells
were cultured on mitotically inactivated mouse embryonic fibro-
blast STO feeder cells in medium consisting of DMEM containing
10% fetal bovine serum (Hyclone, Cat. No. SH30070 or SH30071),
2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomy-
cin, and 0.125 mM b-mercaptoethanol (Robertson, 1987). Freshly
s of reproduction in any form reserved.
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342 Myer, Olson, and Kleinthawed cells were passed at least one time, grown to confluence,
and harvested for embryoid body differentiation using the methods
of Weitzer et al. (1995). The cells were diluted to 2 3 104 cells/ml
n differentiation medium [DMEM containing 15% fetal bovine
erum from Sigma (Cat. No. F-2442, Lot 46H4648 or 69H84211), 2
M L-glutamine, 50 units/ml penicillin, 50 mg/ml streptomycin,
0.143 mM b-mercaptoethanol], from which 20-ml hanging drops
ere made. After 5 days, 50 to 150 drops were pooled and plated
nto a 0.1% gelatin-coated surface. Fresh differentiation medium
as added periodically to the differentiating embryoid bodies when
he indicator dye changed from red to yellow.
ABLE 1
rimers for RT-PCR Analysis
Gene Forward primer
MyoD GACAGGACAGGACAGG
Myf5 TGAATGTAACAGCCCTG
myogenin CCTTTTCCGACCTGATG
MRF4 CTACATTGAGCGTCTAC
FIG. 1. Skeletal muscle differentiation in ES cells. ES cells were
yosin heavy chain. Positive staining shows as reddish-brown. (A
EMSV–MyoD transfection. Differentiated myocytes are either round
nuclei (arrowheads). (C) ES cell line AB2.1. Myofibers or muscle shee
(2/2) parental line after EMSV–myogenin transfection. Muscle sheets
Copyright © 2000 by Academic Press. All rightDNA Transfections and Detection of Gene
Expression
The myogenin-expressing cDNA plasmid (pEMSVMyo8) was
described by Edmondson and Olson (1989). The MyoD-expressing
cDNA plasmid (pEMC11s) was obtained from Andrew Lassar,
Harvard Medical School (Davis et al., 1987), and the hygromycin-
esistant plasmid (pgk-hygro) was obtained from Richard Behringer
M. D. Anderson Cancer Center; Shawlot et al., 1998). Each cDNA
lasmid was introduced into the 2C1 myogenin (2/2) ES cell line
y electroporation along with the hygromycin-resistant plasmid.
Reverse primer
G GCACCGCAGTAGAGAAGTGT
GCACTATCTATTCAGACC
TCCTGGGTTGGGACCGAA
CTGAAGACTGCTGGAGGC
rentiated for 27 days prior to immunohistochemical detection of
cell line D.37 derived from a myogenin (2/2) parental line after
r spindle shaped. (B) ES cell line AB1. Myotubes contain centralized
ck centralized nuclei. (D) ES cell line Y.26 derived from a myogeninGAG
T
GAGdiffe
) ES
ed o
ts laare seen as sheets of connected fibers.
s of reproduction in any form reserved.
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343Myogenin-Deficient ES CellsThe myogenin-expressing plasmid was linearized with SalI, the
yoD-expressing plasmid with XbaI, and the hygromycin-resistant
lasmid with HindIII. All three linearized plasmids were purified
rom residual protein by extraction with phenol/chloroform, pre-
ipitated in ethanol, and resuspended in 10 mM Tris–HCl, pH 8.0,
nd 10 mM EDTA prior to electroporation.
myogenin (2/2) 2C1 ES cells were grown to confluence on STO
eeder cells prior to being harvested for electroporation. Fresh
edium was supplied to the confluent cells for 2 h before digestion
ith trypsin for 10 min. Approximately 4 3 107 cells were washed
three times with PBS and resuspended in 1 ml of PBS with 20 mg of
inearized cDNA plasmid mixed with 2 mg of linearized
hygromycin-resistance plasmid. A Bio-Rad gene pulser (Hercules)
set at 0.23 kV was used to shock the cells; they were then plated
onto nine 10-cm plates containing hygromycin-resistant mitoti-
cally inactivated STO cells (SNL-H; provided by Jim Martin, Texas
A&M University; Shawlot et al., 1998). Drug selection was begun
FIG. 2. Myocyte, myotube, and muscle sheet differentiation in w
MyoD ES cell lines. The histograms represent the percentage of sam
glass slide) for each ES cell line that contained observable myosin h
480 mm in length, and (C) muscle sheets. Each sample was given a
in the sample. N, number of samples analyzed. Het., myogenin (1/
cells constitutively expressing myogenin; MyoDc, myogenin (2/2
enotype is statistically significantly different from the wild-type g
o allow for all three data sets to be presented.24 h later with 86 mg/ml hygromycin B (Sigma, Cat. No. H3274). f
Copyright © 2000 by Academic Press. All rightolonies appeared 10 to 14 days after selection and were picked and
aintained under hygromycin B selection in 96-well plates. Ap-
roximately every third day, the colonies were trypsinized for 3
in. Clones that thrived under these conditions were passed to a
4-well plate with no hygromycin B. Once confluent, each colony
as split among three wells of a 24-well plate. After confluency
as reached, cells from 1 well were used for DNA isolation, cells
rom the second well for RNA isolation, and cells from the third
ere passed to 1 well of a 6-well plate. When these cells reached
onfluency, they were frozen and stored under liquid nitrogen until
urther use.
Clones carrying cDNA plasmids were identified by Southern
ybridization analysis. The genomic DNA was digested with EcoRI
efore electrophoresis and blotting. The corresponding cDNA
lasmids were digested with EcoRI, and cDNA inserts were iso-
ated, radiolabeled, and used as probes for Southern hybridization.
Clones that contained integrated cDNA plasmid were analyzed
pe, myogenin (2/2), and constitutively expressing myogenin and
(pooled of embryoid bodies from a single chamber of a 2-chamber
chain-positive staining in (A) myocytes, (B) myotubes greater than
ity value of 11 to 41 reflecting the density of differentiated cells
cells; Null, myogenin (2/2) ES cells; Myogc, myogenin (2/2) ES
cells constitutively expressing MyoD. Asterisk indicates that the
ype (P # 0.01). Note that the ordinate scale on A, B, and C variesild-ty
ples
eavy
dens
2) ES
) ES
enotor myogenin or MyoD expression by RT-PCR. RNA was isolated
s of reproduction in any form reserved.
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344 Myer, Olson, and Kleinfrom undifferentiated ES cells, and RT-PCR was performed as
described below. The primers used to detect myogenin transcripts
are shown in Table 1. For detecting MyoD transcripts that were
derived from the plasmid, the following primers were used: for-
ward, 59 CAA ATA AAG CAA TAG CAT C 39, and reverse, 59 GTT
TGT CAC TTT CTG GAG 39. The annealing temperature was
59°C.
Immunostaining
Fifty 5-day-old hanging drops containing embryoid bodies were
pooled and dispersed among eight chambers of two-chamber glass
slides (Fisher, Cat. No. 12-565-16) coated with 0.1% gelatin.
Embryoid bodies were differentiated for an additional 22 days
unless otherwise noted and fixed in either acetone (myosin heavy
chain staining) or 1% paraformaldehyde (MyoD staining) at 4°C.
Fixed cells were immunostained using a HistoMouse-SP kit
(Zymed). Antibodies for myosin heavy chain were A4.1025 super-
natant at 1:2 dilution or MF20 ascites at 1:800 dilution, supplied
from the Developmental Studies Hybridoma Bank (Johns Hopkins
University and University of Iowa, Contract N01-HD-6-2915 from
NICHD). For MyoD immunostaining, M-318 at 2.5 mg/ml was used
(Santa Cruz Biotechnology).
RNA Isolation and RT-PCR
One hundred fifty hanging drops were pooled after 5 days of
culture and plated onto a 0.1% gelatin-coated 24-well plate. After
an additional 22 days in culture, plates were examined for contract-
ing skeletal muscle. Up to 5 wells of contracting muscle were
harvested for RNA isolation using the TRI Reagent method (Mo-
lecular Research Center).
Three micrograms of RNA isolated from differentiated embryoid
bodies or 1 mg of RNA from wild-type mouse hindlimbs was reverse
transcribed using Superscript II (Life Technologies). Two microli-
ters of the RT product was used for PCR. Standard PCR conditions
were employed with Roche Taq polymerase and Clontech Taqstart
antibody. For MyoD, myf5, and MRF4, a 5-min “hot start” pre-
ceded 35 cycles of the following: 94°C for 30 s, 65°C for 30 s, and
72°C for 1 min. For myogenin, the annealing temperature was
62°C. The sequences of the primers used for each PCR are shown in
Table 1.
For competitive PCR, the above conditions were used with the
addition of a known concentration of a shortened competitor
plasmid template (Gilliland et al., 1990). The myogenin competitor
plasmid was generated by subcloning a 1.0-kb EcoRI fragment of a
myogenin cDNA into the EcoRI site of pBluescript SK (Stratagene).
To shorten the sequence between the two primer annealing sites, a
102-bp StuI fragment from the myogenin cDNA was deleted by
digesting the subclone with StuI and ligating the resulting short-
ened plasmid. The MyoD competitor plasmid was generated by
subcloning a MyoD cDNA into the EcoRI site of pBluescript SK in
which the EcoO109I was destroyed. The subclone was digested
with EcoO109I to remove an 88-bp EcoO109I fragment from the
cDNA and the shortened cDNA was religated. The myogenin
competitor plasmid was linearized with BamHI prior to use.
Plasmid concentrations were determined by agarose gel electro-
phoresis using standard DNAs of known concentration. One-D
multi (line) densitometry was performed on an Alphaimager 2200
system (Alpha Innotech Corp.) for quantifying the PCR products.
Copyright © 2000 by Academic Press. All rightMorphological and Statistical Analyses
Embryoid bodies stained with myosin heavy chain antibodies
were examined for the presence of positive-staining myocytes,
short myotubes (less than or equal to 480 mm), long myotubes
(greater than 480 mm), and muscle sheets lacking centralized
nuclei. For morphological quantification, each sample, which
represented pooled embryoid bodies from one chamber, was
scored as positive or negative for the presence of any myocytes,
myotubes, or muscle sheets. In addition, each chamber was
scored on a density scale of 0 (none) to 41 (most) to indicate the
xtent of myocyte, myotube, and muscle sheet density in a given
ample. This subjective density scale was necessary because it
as not possible to precisely count the number of myotubes and
uscle sheets within a chamber since they were intermingled
ith one another.
For statistical analysis, each sample was given the value of its
ensity score. The density scores for myocytes, short myotubes,
ong myotubes, or muscle sheets from each ES cell line were added
nd, together with the total number of samples, were analyzed by
. Neely Atkinson and L. B. Levy (M. D. Anderson Cancer Center)
sing ordinal logistic regression with the software package JMP
rom SAS. Pair-wise comparisons were performed between ES cell
enotypes. The predictors were genotype, ES cell line (genotype),
nd time (genotype, ES cell line), where notation “A(B)” indicates
hat variable A is nested in variable B. If either ES cell line or time
as not significant, that variable was then removed from the
odel. P values were computed using likelihood ratio statistics.
RESULTS
myogenin (2/2) ES Cells Are Ineffective in Skeletal
Muscle Differentiation
myogenin-knockout mice make very little skeletal
muscle, even though myoblasts appear to form normally
(Hasty et al., 1993; Nabeshima et al., 1993; Venuti et al.,
1995). Surprisingly, when myogenin (2/2) myoblasts are
isolated from embryos and induced to differentiate in vitro,
they do so with the same efficiency as wild-type myoblasts
(Nabeshima et al., 1993; Rawls et al., 1995). Moreover, in
chimeric mice created with myogenin (2/2) ES cells, myo-
genin (2/2) myoblasts participate efficiently in myofiber
formation as long as sufficient numbers of wild-type myo-
blasts are present (Myer et al., 1997). These results indicate
that the extracellular environment strongly influences the
differentiation capabilities of myogenin (2/2) myoblasts.
Unfortunately, the ability to fuse and differentiate limits
the usefulness of isolated myogenin (2/2) myoblasts as a
tool to study muscle differentiation in vitro. To investigate
myogenin’s role in muscle differentiation more precisely,
we sought to develop an in vitro system that would reflect
the extracellular environment of myogenin (2/2) embryos
and also mimic the skeletal muscle defects associated with
the absence of myogenin.
myogenin (2/2) ES cells were cultured alongside myoge-
nin (1/2) ES cells or wild-type ES cells, and embryoid
bodies generated from these ES cell lines were allowed to
differentiate. In our hands, wild-type embryoid bodies pro-
duced contracting skeletal muscle 20 to 25 days after
s of reproduction in any form reserved.
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345Myogenin-Deficient ES Cellsdifferentiation was induced. Each ES cell line was examined
for the presence of myocytes, myotubes, and muscle sheets
lacking centralized nuclei as determined by their morpho-
logical features and expression of myosin heavy chain.
Myocytes were identified as myosin heavy chain-positive
mononucleate cells that had rounded or spindle-shaped
morphology (Fig. 1A). Myosin heavy chain-expressing tubu-
lar structures with multiple centralized nuclei were desig-
nated myotubes (Fig. 1B), and enlarged syncytial tubes or
sheets in which nuclei were no longer apparent were
defined as muscle sheets (Figs. 1C and 1D). myogenin (2/2)
ES cells produced myocytes and myotubes in numbers that
were not statistically different from the numbers for wild-
type or myogenin (1/2) controls (Figs. 2A and 2B). These
results were not unlike those observed in vivo, in which
myogenin (2/2) embryos had appreciable levels of myosin-
and MyoD-positive mononucleate cells and poorly differen-
tiated fibers (Hasty et al., 1993; Nabeshima et al., 1993;
enuti et al., 1995).
In contrast to results for myocytes and myotubes, major
ifferences were found in the number of muscle sheets
hen myogenin (2/2) ES cells were compared with wild-
ype or heterozygous ES cells (Figs. 2C and 3C). The
ercentage of samples, where a sample is defined as pooled
mbryoid bodies from a single immunostained chamber,
rom wild-type and myogenin (1/2) ES cells that produced
uscle sheets ranged from 15 to 28%, whereas less than 4%
f the samples from myogenin (2/2) ES cells produced
uscle sheets. Moreover, the myogenin (2/2) samples
roducing muscle sheets rarely had fiber density values
reater than 11, whereas values of control samples ranged
rom 11 to 41 (Fig. 2C). The differences between myogenin
(2/2) and wild-type ES cells were highly significant (P ,
0.0001) and were reproducible in multiple independent ES
cell clones of each genotype. These results demonstrate
that myogenin (2/2) ES cells closely resemble myogenin
(2/2) embryos in their inability to form differentiated
skeletal muscle.
Restoration of Muscle Sheets in myogenin (2/2) ES
Cells by Constitutive Expression of Myogenin
To ensure that the absence of myogenin was directly
responsible for the observed defects in skeletal muscle
differentiation in myogenin (2/2) ES cells, we introduced
xogenous myogenin into these ES cells under the control
of the constitutive EMSV promoter. Two representative ES
cell lines expressing myogenin were selected and induced to
differentiate alongside the parental myogenin (2/2) ES cell
lines and the wild-type and myogenin (1/2) controls. The
two myogenin-expressing ES cell lines produced muscle
sheets at least as effectively as wild-type or heterozygous
controls (Figs. 2C, 4A, and 4B), whereas the parental line,
which was transfected with only the hygromycin expres-
sion vector, did not differentiate into skeletal muscle sheets
(Fig. 2C).Qualitative differences were observed between constitu-
Copyright © 2000 by Academic Press. All rightively expressing myogenin ES cells and wild-type or het-
rozygous controls. Both myogenin-expressing lines formed
higher percentage of muscle sheets (29 to 38% compared
ith 15 to 28%; Fig. 2C). In addition, samples from the
yogenin-expressing ES cells tended to make larger muscle
heets (Figs. 4A and 4B). This difference was reflected in
ower muscle sheet density values for the myogenin-
xpressing lines (Fig. 2C). The reason for qualitative differ-
nces in muscle sheet formation between endogenously and
xogenously expressing myogenin ES cells is not known but
ight involve a lack of temporal or quantitative regulation
n the constitutively expressing lines.
To determine the levels of myogenin that were expressed
n the constitutive ES cell lines, we quantified myogenin
ranscripts using competitive RT-PCR (Gilliland et al.,
990). One line expressed myogenin at levels equivalent to
hose of wild-type or heterozygous ES cells, while a second
ine expressed five times more myogenin transcript (Table
). Because no appreciable differences were observed in
uscle sheet formation between the two constitutively
xpressing lines, these results indicated that myogenin
ould function efficiently in this differentiation system
ver a fivefold range of expression levels.
MyoD is expressed at normal levels in myogenin (2/2)
mbryos (Hasty et al., 1993; Rawls et al., 1995). To deter-
ine the extent of MyoD expression in differentiated myo-
genin (2/2) embryoid bodies, we determined MyoD expres-
sion levels by competitive RT-PCR. One myogenin (2/2)
ES cell line expressed MyoD at levels comparable to those
of wild-type controls while two others expressed MyoD at
25% of controls, yet none of these lines was able to form
differentiated muscle sheets (Table 2). Although not con-
clusive, these results suggest that the presence of MyoD
was not adequate for muscle sheet differentiation in myo-
genin (2/2) ES cells. This supports earlier in vivo analyses
showing that endogenous expression of MyoD was insuffi-
cient to promote skeletal muscle differentiation in the
absence of myogenin. In contrast, the two constitutively
expressing myogenin lines had attenuated levels of MyoD
transcript (Table 2). One line expressed MyoD at only
17% of wild-type levels, while the other line had unde-
tectable levels. The reason for the low levels of MyoD in
these myogenin-expressing ES cells is unclear, but none-
theless low MyoD levels did not prevent robust muscle
sheet formation in the presence of appropriate levels of
myogenin.
Inability of Constitutive Expression of MyoD to
Restore Muscle Sheet Formation in Differentiating
myogenin (2/2) ES Cells
Because myogenin and MyoD have similar muscle-
inducing behavior in tissue culture cells, constitutive ex-
pression of MyoD in myogenin (2/2) ES cells should be a
stringent test of functional redundancy between myogenin
and MyoD. We therefore introduced MyoD into myogenin
(2/2) ES cells under the control of the same EMSV pro-
s of reproduction in any form reserved.
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347Myogenin-Deficient ES Cellsmoter that we used for constitutive myogenin expression.
Two MyoD-expressing lines were selected and induced to
differentiate. Both lines showed the same characteristics;
most importantly, they did not produce substantial quanti-
ties of muscle sheets (Fig. 4C). The percentage of samples
that produced muscle sheets was only slightly higher than
for myogenin (2/2) ES cell lines, and these samples never
had muscle sheet density values above 11 (Fig. 2C).
Although skeletal muscle sheet formation in the MyoD-
expressing myogenin (2/2) ES cells was inefficient, we did
observe a significant increase in the number of myocytes
(P , 0.001; Fig. 2A). This increase was reflected in the
higher myocyte density values for individual samples of
MyoD-expressing embryoid bodies (Fig. 2A). In the MyoD-
expressing line D.32, 90% of samples analyzed had density
values of 21 and 31, and line D.37 had 60% of samples
with values of 41. All other ES cell lines that we differen-
tiated had substantially fewer numbers of myocytes (Fig.
2A). This increase in myocyte number suggests the possi-
bility that constitutive expression of MyoD in the absence of
myogenin efficiently converted naı¨ve cells to the myogenic
lineage but also that, without myogenin, most of these cells
were unable to fully differentiate into skeletal muscle sheets.
However, a conclusive demonstration that forced expression
of MyoD led to the recruitment of additional myoblasts awaits
a precise comparison of the number of myoblasts in MyoD-
expressing and MyoD-nonexpressing lines.
We confirmed that forced expression of MyoD increased
the number of myocytes using immunohistochemical de-
tection of MyoD in differentiated embryoid bodies. In
wild-type embryoid bodies, MyoD was found mostly in the
nuclei of single cells (Fig. 5A), and little expression was
found in myotubes (Fig. 5B), indicating that its expression
decreased following muscle differentiation. MyoD was
abundantly expressed, and a greater number of MyoD-
positive nuclei were found in single cells of the two
MyoD-expressing lines (Fig. 5C). These results offer a dra-
matic example of the inability of MyoD to promote muscle
differentiation in the absence of myogenin. Although large
amounts of MyoD were expressed in the nuclei of these
cells, they were nevertheless unable to fuse and form
muscle sheets (Fig. 5C).
The two MyoD-expressing myogenin (2/2) ES cell lines
expressed high levels of MyoD transcript, as determined by
competitive RT-PCR. Thus, one line expressed 4 times
more MyoD transcript compared with wild-type levels,
while the other line expressed 29 times more (Table 2).
Although abundant MyoD levels were found in these cells,
they were unable to make significant amounts of muscle
sheets without myogenin.
The Formation of Muscle Sheets Correlates with
myogenin Transcript Expression but Not with the
Other Myogenic bHLH Regulators
Using qualitative RT-PCR, we determined which myo-
genic bHLH factors correlated with muscle sheet formation
Copyright © 2000 by Academic Press. All rights of reproduction in any form reserved.
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348 Myer, Olson, and Kleinin differentiating ES cells. We used wild-type, myogenin
(1/2), myogenin (2/2), constitutively expressing myoge-
nin, and constitutively expressing MyoD ES cells to detect
the expression of MyoD, myf5, MRF4, and myogenin. We
nvariably observed muscle sheet formation when myoge-
in transcripts were expressed (Fig. 6, lanes 1, 2, 3, 7, and 8).
onversely, we never observed efficient muscle sheet for-
ation when we did not detect myogenin transcripts (Fig.
6, lanes 4, 5, 6, 9, and 10). In contrast, myf5 and MRF4
xpression was detected in myogenin (2/2) ES cells and in
yoD-expressing myogenin (2/2) ES cells (Fig. 6, lanes 4,
, 6, and 10), although these cells were ineffective in
aking muscle sheets. Although the RT-PCR results were
ualitative, they provided further evidence that myogenin
as distinct functions that cannot be replaced by the other
yogenic factors.
TABLE 2
Detection of myogenin and MyoD Transcripts by Competitive RT
%
WT
Het
No. 17AB1 AB2.1 No. 18
MyoD 100 100 100 25
yogenin 100 100 100 ND
a Wild-type and myogenin (1/2) ES cell lines have equivalent am
T-PCR. These levels were normalized to a value of 100%. ND, n
FIG. 6. Muscle sheet differentiation correlates with myogenin
expression. ES cell lines were differentiated for 27 days prior to
RNA isolation. RT-PCR was performed to detect MyoD, myf5,
MRF4, and myogenin transcripts. The PCR products were electro-
phoresed on 2% agarose gels. Lanes 1 and 2 are wild-type ES cells
(AB1 and AB2.1). Lane 3 is myogenin (1/2) ES cell line No. 17.
Lanes 4, 5, and 6 are myogenin (2/2) ES cell lines No. 18, 2C1, and
Y.2. Lanes 7 and 8 are myogenin (2/2) ES cell lines constitutively
expressing myogenin (Y.6 and Y.26). Lanes 9 and 10 are myogenin
(2/2) ES cell lines constitutively expressing MyoD (D.32 and
D.37). Lane 11 represents PCR products from RT-PCR performed
on RNA isolated from the hind limb of a myogenin (1/2) E18.5nembryo.
Copyright © 2000 by Academic Press. All rightDISCUSSION
Myogenin versus MyoD
The differentiation properties of myogenin (2/2) ES cells
have allowed us to define an important functional role for
myogenin in skeletal muscle formation that cannot be
replaced by MyoD. Despite being expressed under identical
conditions, MyoD was unable to promote muscle sheet
formation in myogenin (2/2) ES cells. Throughout this re-
ort, we have used the term muscle sheets as an operational
efinition to indicate extensive skeletal muscle differentia-
ion. However, further analysis would be required to fully
haracterize the myofiber properties associated with these
uscle sheets in differentiating embryoid bodies.
Because the myogenic cDNAs were expressed under the
onstitutive regulation of the EMSV promoter, the observed
ifferences between myogenin and MyoD are not likely to
e explained by differences in temporal expression. More-
ver, cell types are highly intermingled in differentiated
mbryoid bodies, implying that myogenin can function
fficiently in the absence of spatially organized progenitor
ells. However, EMSV-driven MyoD did not result in MyoD
xpression in all ES cells at 27 days of culture and it is
ormally possible that the two myogenic factors were ex-
ressed in subpopulations with different morphological
apabilities.
Although previous investigations indicated that MyoD
nd myogenin performed different roles in myogenesis
commitment versus differentiation), these earlier studies
id not determine whether the different roles were due to
ifferences in protein sequence or regulation of gene expres-
ion (reviewed in Arnold and Braun, 2000). Our experiments
rovide strong evidence that myogenin and MyoD behave
ifferently in muscle sheet formation and that, without
yogenin, MyoD cannot promote the robust myocyte fu-
ion processes necessary for extensive skeletal muscle dif-
erentiation. Thus, myogenin is likely to have functional
omains that promote muscle sheet formation that are
acking in MyoD. The results presented here complement
hose of Gerber et al. (1997), who showed that MyoD has
hromatin remodeling domains within its sequence that are
d-type transcriptsa
Null Myogc MyoDc
2C1 Y.2 Y.6 Y.26 D.32 D.37
100 25 17 ND 400 2900
ND ND 500 100 ND ND
s of myogenin and MyoD transcripts as determined by competitive
tectable levels.-PCR
wil
ountot present within myogenin.
s of reproduction in any form reserved.
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349Myogenin-Deficient ES CellsBoth MyoD and myogenin harbor transcriptional activa-
tion domains, but these do not share any discernable
similarities (Weintraub et al., 1991; Schwarz et al., 1992;
inkel et al., 1993; Gerber et al., 1997). Although our
analysis has not identified a muscle sheet-promoting do-
main within the myogenin sequence per se, our expectation
is that such a domain exists and would be able to enhance
transcription at E-box-containing enhancers in conjunction
with the E family of bHLH proteins. E proteins dimerize
with the myogenic bHLH factors to greatly enhance DNA
binding and transcriptional activation of muscle-specific
genes (Blackwell and Weintraub, 1990; Finkel et al., 1993).
n addition, MEF2 proteins cooperate with the myogenic
HLH factors to stimulate transcription at E-box or MEF2
ites (Molkentin and Olson, 1996). Myogenin–E protein–
EF2 complexes may act more efficiently as transcrip-
ional activators at DNA regulatory elements of muscle
enes that act late in the myogenic pathway than the
orresponding MyoD complexes, which would be predicted
o act selectively on early myogenic genes. It is also
onceivable that transcriptional repression or signaling
athways act selectively on myogenin or MyoD (Lu et al.,
000).
ES cells lacking myogenin produced myosin-positive
yocytes and myotubes as efficiently as did wild-type ES
ells. We are not sure why myogenin was required for the
ormation of muscle sheets but was not essential for other
spects of myogenesis. The process of cell fusion appears to
e particularly sensitive to myogenin’s absence in differen-
iating ES cells and in vivo. myogenin (2/2) myoblasts fuse
fficiently in genetic chimeras and in isolated culture,
ndicating that myogenin may control genes that are criti-
al for producing a fusion-promoting extracellular environ-
ent (Nabeshima et al., 1993; Rawls et al., 1995; Myer et
l., 1997). For activation, these genes may require the
pecific features of myogenin that are not included within
he MyoD sequence.
Functional versus Regulatory Differences among
the Myogenic bHLH Factors
Although a simple model in which MyoD and myogenin
have distinct sequences that are dedicated to either com-
mitment or differentiation is appealing, the relationship
among the myogenic bHLH factors and their role in myo-
genesis is far more complex. MyoD has genetically redun-
dant functions both in myoblast commitment and in differ-
entiation, as evidenced by the phenotype of MyoD (2/2):
yf5 (2/2) or MyoD (2/2):MRF4 (2/2) double-knockout
mice (Rudnicki et al., 1993; Rawls et al., 1998). MyoD:myf5
ouble-knockout mice fail to form myoblasts and thus form
o skeletal muscle. In contrast, in MyoD:MRF4 double-
knockout mice, myoblasts form and migrate to their appro-
priate location, but as in myogenin (2/2) mice, most of the
myoblasts do not fuse to form skeletal muscle. Triple-
knockout mice lacking myogenin, MyoD, and MRF4 have
more severe muscle deficiencies than myogenin (2/2) mice
Copyright © 2000 by Academic Press. All rightor MyoD (2/2):MRF4 (2/2) double-knockout mice. Myo-
blasts are present but even fewer myofibers form in the
triple knockout, suggesting that the redundant functions of
MyoD and MRF4 in muscle differentiation do not overlap
with the functions of myogenin (Valdez et al., 2000). The
genetic redundancies among the myogenic factors make
mammalian skeletal muscle formation a robust differentia-
tion system. The phenotypes of the compound mutant mice
suggest that a dynamic genetic regulatory network exists
among the myogenic bHLH factors in which positive and
negative feedback loops and compensatory fail-safe mecha-
nisms ensure the orderly progression of the myogenic
differentiation program. Within and downstream of this
genetic network, each myogenic factor is likely to control a
distinct set of muscle genes based on its specialized func-
tion and regulated expression.
Although our analysis emphasized individual functional
distinctions between MyoD and myogenin, transcriptional
regulation of myogenic factor gene expression also plays an
important role. Each factor must be expressed in a distinct
temporal, spatial, and quantitative pattern for it to function
appropriately. In support of this is the fact that when
expressed prematurely or at levels only slightly below those
present in myogenin (1/2) mice, myogenin cannot func-
tion effectively (Wang et al., 1996; Vivian et al., 1999).
myogenin (2/2) ES cells should be particularly useful in
identifying functional domains that impart muscle sheet-
forming capabilities to myogenin. By creating protein chi-
meras between MyoD and myogenin, it should be possible
to determine whether sequences present on myogenin can
replace corresponding sequences on MyoD and lead to
muscle sheet formation in differentiating myogenin (2/2)
ES cells.
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